VMA21

Across TCGA pan-cancer cohorts, VMA21 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated VMA21 data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher VMA21 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated VMA21 expression acts as an unfavorable survival marker, although some lineages such as HNSC and COAD show a favorable association.

HNSC, COAD, and LUAD are the cancer types where VMA21 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	1.000	0.905	<.001	48	view →
COAD	DFS	Median	III,IV	1.000	0.828	.038	24	view →
LUAD	OS	Median	II,III,IV	0.293	0.837	<.001	7	view →
PDAC	DFS	Tertile	All	0.288	0.603	.030	5	view →
LSCC	DFS	Quartile	All	0.802	0.535	.023	4	view →
GBM	DFS	Quartile	All	0.273	0.484	.034	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

VMA21–HNSC (DFS)

Open the HNSC breakdown →